George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.00
Bid: 1.95
Ask: 2.05
Change: 0.00 (0.00%)
Spread: 0.10 (5.128%)
Open: 2.00
High: 2.00
Low: 2.00
Prev. Close: 2.00
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Shield Therapeutics appoints chief medical officer

Mon, 27th Sep 2021 14:26

(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Monday that Dr Jose Menoyo is joining its senior executive team as vice-president and chief medical officer, with immediate effect.
The AIM-traded firm said that before joining Shield, Dr Menoyo served as head of United States medical affairs at Alexion Pharmaceuticals, a publicly-traded biotechnology company acquired by AstraZeneca in July.

In that role, he led the medical affairs and health outcomes and research teams, supporting a number of launches in the rare disease area.

Prior to his role at Alexion, Dr Menoyo was the senior vice-president of clinical development and medical affairs for ZS Pharma, which was also eventually acquired by AstraZeneca.

Previous biopharmaceutical experience included leadership roles at Amgen, Genzyme and Sanofi.

Dr Menoyo completed his internal medicine and nephrology fellowship at Hahnemann University Hospital and Medical College of Pennsylvania, and would be reporting to chief executive officer Greg Madison.

"Dr Menoyo brings more than 25 years of experience in medical affairs, drug development and regulatory leadership across both large and small publicly-traded biopharmaceutical companies which includes successful drug global launches and commercialisation support," said Greg Madison.

"Dr Menoyo has extensive US and global experience in building and leading high-performing teams, and his particular and proven expertise in establishing and executing medical affairs strategies will be extremely valuable to Shield for the launch of Accrufer in the US."

Shield also confirmed that, further to its announcement on 28 May, Tim Watts was resigning from the board with effect from 30 September, and would no longer have any role with the group from that date.

"I would like to thank Tim for his crucial role in bringing Shield to the point at which Accrufer can be launched in the US and wish him well for the future."

At 1241 BST, shares in Shield Therapeutics were down 2.02% at 41.15p.
More News
21 Feb 2024 16:57

LONDON MARKET CLOSE: FTSE 100 takes hit ahead of FOMC minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors anxiously look ahead to this evening's Federal Open Market Committee meeting minutes.

Read more
21 Feb 2024 12:36

Shield Therapeutics sinks as strong performance marred by data issues

(Alliance News) - Shield Therapeutics PLC on Wednesday said that it was expecting stellar results for 2023, but this success was overshadowed by a mistake in the company's previous prescription forecasts.

Read more
9 Jan 2024 11:33

IN BRIEF: Shield Therapeutics hires former Akili leader as new CFO

Shield Therapeutics PLC - Commercial-stage pharmaceutical company focused on iron deficiency product Accrufer - Hires Santosh Shanbhag as chief financial officer, effective next Tuesday. He replaces Hans-Peter Rudolf, who left Shield in October to pursue new opportunities. Shanbhag was previously CFO of Nasdaq-listed Akili Inc, which he "helped transform...from a private to a public entity". Before this, he held various senior finance leadership roles at Vertex Pharmaceuticals Inc, including as Head of International Finance & Accounting.

Read more
7 Dec 2023 15:31

TRADING UPDATES: Comptoir opens restaurant; Intercede wins contract

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
7 Dec 2023 13:11

Shield Therapeutics reports strong US progress

(Sharecast News) - Iron deficiency-focussed pharmaceuticals company Shield Therapeutics announced significant achievements in the US commercialisation of Accrufer on Thursday.

Read more
12 Oct 2023 11:14

IN BRIEF: Shield Therapeutics Chief Financial Officer Rudolf to leave

Shield Therapeutics PLC - commercial-stage pharmaceutical company focusing on its iron deficiency product Accrufer - Chief Financial Officer Hans-Peter Rudolf will leave the company next week Friday to pursue other opportunities. The firm's company controller, Paul Spoors, will take on the CFO role on an interim basis. Shield says it has engaged an executive search firm to identify a new CFO.

Read more
12 Oct 2023 10:27

AIM WINNERS & LOSERS: Windward sees high contracting activity levels

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
3 Oct 2023 17:14

TRADING UPDATES: Aston Martin CEO ups stake; Alkemy's lithium deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
3 Oct 2023 14:29

Shield Therapeutics completes USD20 million SWK financing

(Alliance News) - Shield Therapeutics PLC on Tuesday said it has now completed its USD20 million senior secured debt facility from SWK Funding LLC.

Read more
28 Sep 2023 14:54

UPDATE: Shield Therapeutics completes GBP5 million share placing

(Alliance News) - Shield Therapeutics PLC on Thursday announced steps to improve its financial situation, as it revealed a slightly reduced loss in the first half of 2023.

Read more
28 Sep 2023 11:30

Shield Therapeutics raises funds for US sales push as loss narrows

(Alliance News) - Shield Therapeutics PLC on Thursday announced steps to improve its financial situation, as it revealed a slightly reduced loss in the first half of 2023.

Read more
21 Sep 2023 15:48

UK earnings, trading statements calendar - next 7 days

Friday 22 September 
Ascential PLCHalf Year Results
Ergomed PLCHalf Year Results
First Tin PLCHalf Year Results
t42 IoT Tracking Solutions PLCHalf Year Results
t42 IoT Tracking Solutions PLCTrading Statement
Monday 25 September 
Alphawave IP Group PLCHalf Year Results
Devolver Digital IncHalf Year Results
Dialight PLCHalf Year Results
Getech Group PLCHalf Year Results
Ondine Biomedical IncHalf Year Results
Real Estate Investors PLCHalf Year Results
SpaceandPeople PLCHalf Year Results
Spectra Systems CorpHalf Year Results
Transense Technologies PLCFull Year Results
Venture Life Group PLCHalf Year Results
Wilmington PLCFull Year Results
Tuesday 26 September 
Alliance Pharma PLCHalf Year Results
AG Barr PLCHalf Year Results
Animalcare Group PLCHalf Year Results
Asos PLCTrading Statement
Boku IncHalf Year Results
Card Factory PLCHalf Year Results
Cambridge Cognition Holdings PLCHalf Year Results
Close Brothers Group PLCFull Year Results
Diaceutics PLCHalf Year Results
DigitalBox PLCHalf Year Results
Dillistone Group PLCHalf Year Results
EKF Diagnostics Holdings PLCHalf Year Results
Ferguson PLCFull Year Results
Finsbury Food Group PLCFull Year Results
IQGeo Group PLCHalf Year Results
Learning Technologies Group PLCHalf Year Results
LifeSafe Holdings PLCHalf Year Results
Mission Group PLCHalf Year Results
Mortgage Advice Bureau Holdings PLCHalf Year Results
NAHL Group PLCHalf Year Results
Next 15 Group PLCHalf Year Results
Newmark Security PLCFull Year Results
NIOX Group PLCHalf Year Results
Origin Enterprises PLCFull Year Results
PZ Cussons PLCFull Year Results
Safestay PLCHalf Year Results
Smiths Group PLCFull Year Results
Time Finance PLCFull Year Results
tinyBuild IncHalf Year Results
Wentworth Resources PLCHalf Year Results
Yu Group PLCHalf Year Results
Wednesday 27 September 
Amicorp FS (UK) PLCHalf Year Results
Aquila European Renewables PLCHalf Year Results
Arix Bioscience PLCHalf Year Results
Avingtrans PLCFull Year Results
Bens Creek Group PLCFull Year Results
Biome Technologies PLCHalf Year Results
BioPharma Credit PLCHalf Year Results
Chapel Down Group PLCHalf Year Results
Everyman Media Group PLCHalf Year Results
Fadel Partners IncHalf Year Results
NCC Group PLCFull Year Results
Old Mutual LtdHalf Year Results
Pantheon Infrastructure PLCHalf Year Results
Pendragon PLCFull Year Results
Plant Health Care PLCHalf Year Results
Safestyle UK PLCHalf Year Results
Saga PLCHalf Year Results
Skillcast Group PLCHalf Year Results
Surface Transforms PLCHalf Year Results
Xeros Technology Group PLCHalf Year Results
Zinc Media Group PLCHalf Year Results
Thursday 28 September 
Atlantic Lithium LtdFull Year Results
Avacta Group PLCHalf Year Results
Avation PLCFull Year Results
Celadon Pharmaceuticals PLCHalf Year Results
Ceres Power Holdings PLCHalf Year Results
Dar Global PLCHalf Year Results
eEnergy Group PLCFull Year Results
HSS Hire Group PLCHalf Year Results
Microlise Group PLCFull Year Results
Novacyt SAHalf Year Results
Phoenix Spree Deutschland LtdHalf Year Results
RBG Holdings PLCHalf Year Results
Shield Therapeutics PLCHalf Year Results
Silver Bullet Data Services Group PLCHalf Year Results
Trellus Health PLCHalf Year Results
Trinity Exploration & Production PLCHalf Year Results
XLMedia PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
6 Sep 2023 20:33

IN BRIEF: Shield Therapeutics changes reporting currency to US dollars

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Says it will change reporting currency to US dollars from pound sterling from 2023 results. Says the interim results for the first half of 2023 will include condensed and consolidated US dollar financial information for the period and full-year 2022.

Read more
6 Aug 2023 17:07

CORRECT: Biogens, Sage Therapeutics postpartum depression drug okayed

(Correcting the name of Sage Therapeutics Inc. Please ignore incorrect coding of Shield Therapeutics PLC.)

Read more
6 Aug 2023 14:17

Biogens, Sage Therapeutics postpartum depression treatment approved

(Alliance News) - The US Food & Drug Administration has approved Zurzuvae, zuranolone, 50 mg for adults with postpartum depression, Sage Therapeutics PLC and Biogen Inc said in a statement.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.